🔗 Visit the ClinicalTrials.gov page for NCT02042027
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Corneal neovascularization. | Curr Opin Ophthalmol | 2001 | 3.22 |
| 2 | Intravenous transferrin, RGD peptide and dual-targeted nanoparticles enhance anti-VEGF intraceptor gene delivery to laser-induced CNV. | Gene Ther | 2009 | 1.34 |
| 3 | Nanoparticles sustain expression of Flt intraceptors in the cornea and inhibit injury-induced corneal angiogenesis. | Invest Ophthalmol Vis Sci | 2007 | 1.25 |
| 4 | Corneal neovascularization: an anti-VEGF therapy review. | Surv Ophthalmol | 2012 | 1.21 |
| 5 | Targeted intraceptor nanoparticle therapy reduces angiogenesis and fibrosis in primate and murine macular degeneration. | ACS Nano | 2013 | 0.91 |
| 6 | Flt23k nanoparticles offer additive benefit in graft survival and anti-angiogenic effects when combined with triamcinolone. | Invest Ophthalmol Vis Sci | 2012 | 0.85 |
| 7 | Advanced drug delivery and targeting technologies for the ocular diseases. | Bioimpacts | 2016 | 0.76 |